Default company panoramic image
B8bb461e ef80 43ed a87a 738c55f12394

Gila Therapeutics, Inc.

We are developing a simple and safe therapy to address the $150B obesity market. Far more effective than existing therapies with zero safety issues.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Minneapolis, MN, US
  • Currency USD
  • Founded April 2014
  • Employees 1
  • Incorporation Type C-corp
  • Website

Company Summary

"Feel Full Faster"
Gila is developing a pharmaceutical product that delivers a natural human protein to the tongue to induce fullness by stimulating the satiety center in the brain. We are developing a simple and safe solution for the obesity epidemic and expect to receive FDA approval within five years though we plan to partner with a large pharma within three years for marketing and sales, and to support development.


  • Ebebd4bc 947c 4a4f beb5 bf61a66c6771
    CEO & Co-Founder

    Extensive startup experience – Millennium, LabSeek, Lynx, HTG & others; established new ventures within Corning, Medtronic and Roche. In the 1990s he began working with obesity genes at Millennium; then in the 2000s at Medtronic, he used insulin pumps to deliver satiety proteins to human subjects with obesity. He has successfully raised financing, developed products & managed M&A. He has 26 publications, 2 issued patents & 2 applications.

  • 3a1b7e5b 34e6 45aa 8a13 1ffb2c5ff7ff
    Gastroenterology and Hepatology Fellow at Mayo Clinic

    MD from USF de Quito, Ecuador in 2006 & PhD from U of FL, USA, in 2009, thesis in Physiology & Pharmacology, the “Role of satiation gut hormones in food intake.” As physician scientist, published 35 peer-reviewed articles, 2 patents.
    Currently, he is specializing in GI & Hepatology at Mayo Clinic; studies satiation gut hormones, obesity & diabetes. He is a co-principal investigator in multiple studies related with obesity & diabetes.


  • 827aa6fe b1fa 4f3d adf8 b07187eed926
    Professor and Associate Executive Director for Clinical Research at the Pennington Biomedical Research Center

Previous Investors

  • Default avatar
    Christopher de Souza, Broadview Ventures